← Leaderboards
Michael M Binkley
Opencell Technologies, Inc.
$1,760,111
Attributed
$1,760,111
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2021–22$2M$1.5M$1M$500K$0
'21
'22
Funding mix
By agency
NIH$1,760,111 · 1
By mechanism
R44$1,760,111 · 1
Top collaborators
No co-investigators on record.
Most similar at Opencell Technologies, Inc.
Same institution · by research overlap
- John Mark Meacham$2,738,057
Others in their field
Other Emerging Leaders on “Allogenic”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$12,837,112
- Elizabeth Holly Payne · The Emmes Company, Llc$5,133,237
- Pietro Genovese · Dana-Farber Cancer Inst$4,879,104
- Sumithira Vasu · Ohio State University$4,852,591
Research focus
AllogenicAreaAutologousBaseBiological SciencesBiophysicsB-Lymphocyte SubsetsB Lymphoid MalignancyBuffersCancer TherapyCar T Cell TherapyCase-By-Case BasisCd19 GeneCd7 GeneCell InjuryCellsCell SurvivalCell TherapyCell TypeCellular EngineeringCellular MembraneCharacteristicsChimeric Antigen Receptor T CellsAcoustics